黑料网

Abstract

Platelet-rich fibrin matrix (PRFM) acts as a scaffold to aid in the function of the cells contained within platelet rich plasma (PRP). In contrast to PRP, PRFM does not contain any coagulation additives, and it naturally forms a fibrin matrix clot which restricts the growth factor release to the clotting site. When the tissue begins to repair itself, it recruits fibroblasts to reorganize the fibrin matrix and starts building collagen. The trial being presented here studied the effects of PRFM on chronic DFUs older than 3 months. 25 patients were screened for the study, with 14 patients completing the trial. 8/14 (57.14%) had complete closure prior to or at the study endpoint of 12 weeks. This compares well with other cellular/tissue-based products available. Among the entire cohort, 13 patients (92.9%) had 50% or greater wound reduction by Week-12. No significant adverse events were determined to be related to PRFM. Based on our findings, PRFM is an effective way to treat challenging DFUs.